Alto Neuroscience Secures $120M Financing, Jefferies Sees 41% Upside
Jefferies set Alto Neuroscience’s price target at $35, implying 41.24% upside after the company secured approximately $120 million in private placement financing for its neuropsychiatric treatment pipeline. Shares surged 9.75% to a one-year high on strong investor demand.
1. Jefferies Price Target and Upside Potential
Jefferies analyst Andrew Tsai set a $35 price target for Alto Neuroscience shares, reflecting a projected 41.24% upside from recent trading levels. This bullish outlook underscores confidence in the company’s precision medicine approach to neuropsychiatric disorders.
2. $120M Private Placement Financing Details
Alto Neuroscience raised about $120 million in a private placement to advance clinical and regulatory efforts across its neuropsychiatric treatment candidates. Proceeds will support upcoming trials and potential commercialization pathways for its precision therapies.
3. Surge to One-Year High on Strong Demand
Shares jumped 9.75%, reaching a one-year high as investors reacted to the financing and positive valuation outlook. Trading volume exceeded 512,000 shares and market capitalization stands near $759 million, signaling heightened market engagement.